A company formed by UW-Madison stem cell pioneer Jamie Thomson today announced that it has entered into an agreement with Roche Palo Alto, one of pharmaceutical giant Roche’s five research facilities, to test candidate drug compounds for cardiotoxicity, or damage to heart tissue.
Under the agreement, Roche will supply Madison-based Cellular Dynamics International Inc. with two sets of 25 well-characterized drug compounds to validate CDI’s current toxicology products and services.